



**University of
Zurich**^{UZH}

**Zurich Open Repository and
Archive**

University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch

Year: 2015

Long-term adverse effects of extracorporeal shock-wave lithotripsy for nephrolithiasis and ureterolithiasis: a systematic review

Fankhauser, Christian D; Kranzbühler, Benedikt; Poyet, Cédric; Hermanns, Thomas; Sulser, Tullio;
Steurer, Johann

DOI: <https://doi.org/10.1016/j.urology.2014.12.014>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-110509>

Journal Article

Accepted Version



The following work is licensed under a Creative Commons: Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.

Originally published at:

Fankhauser, Christian D; Kranzbühler, Benedikt; Poyet, Cédric; Hermanns, Thomas; Sulser, Tullio;
Steurer, Johann (2015). Long-term adverse effects of extracorporeal shock-wave lithotripsy for nephrolithiasis and ureterolithiasis: a systematic review. *Urology*, 85(5):991-1006.

DOI: <https://doi.org/10.1016/j.urology.2014.12.014>

Long term adverse effects of extracorporeal shock-wave lithotripsy for nephro- and ureterolithiasis: A systematic review

Fankhauser CD, Kranzbühler B, Poyet C, Hermanns T, Sulser T, Steurer J

Acknowledgments: We thank Dr. Martina Gosteli for literature search and for the support in organizing the literature research.

Key words: Lithotripsy, Urolithiasis, adverse events, Diabetes Mellitus, Renal Insufficiency. Hypertension

Author contributions: CDF had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: CDF, JS

Acquisition of data: CDF, BK

Analysis and interpretation of data: CDF, BK, JS

Drafting of the manuscript: CDF, JS

Critical revision of the manuscript for important intellectual content: CDF, JS, CP, TH, TS

Obtaining funding: none

Administrative, technical, or material support: None.

Supervision: JS

Financial disclosures: I certify that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (e.g., employment/ affiliation, grants or funding, consultancies, honoraria,

stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: None.

This study presents a systematic review of the published literature on possible long-term adverse effects after extracorporeal shock wave lithotripsy (ESWL). While published disagreement exists, this review finds that previous evidence supporting an association between ESWL and long-term adverse effects is weak, and that the majority of studies show no evidence for any increase in post-ESWL incidence of arterial hypertension (24 of 30 studies), diabetes mellitus (4 of 6 studies), kidney dysfunction (14 of 14 studies), or infertility (2 of 2 studies). Currently, no strong evidence exists to support the hypothesis that ESWL causes long-term adverse effects.

Introduction

Extracorporeal shock wave lithotripsy (ESWL) is a noninvasive treatment option for nephro- and ureterolithiasis. Since its introduction in the 1980s, millions of patients have benefited, and ESWL quickly became the gold standard therapy for nephro- and ureterolithiasis. Known short-term side effects of ESWL are renal hematoma, infectious complications, “steinstrasse” (“stone street”) blockage caused by remaining stone fragments, renal colic, or regrowth of urinary calculi.¹ However, long-term adverse effects (LAE) have not been thoroughly evaluated to date, and several authors have reported contradictory results. Potential LAE of ESWL include arterial hypertension (HTN), diabetes mellitus (DM), chronic kidney disease (CKD), and decreased fertility (FERT). Because no large prospective studies have been conducted to observe LAE after ESWL, we synthesize the published evidence regarding the four most discussed LAE in this systematic review.

Methods

This systematic review was conducted in accordance with the recommendations of the PRISMA statement² and a recent publication about reporting adverse events in systematic reviews.³

Literature search

We conducted a literature search on December 19, 2013 using the following databases: Embase, Scopus, Cochrane, Medline, and Web of Science. For our literature research we used combinations of search terms related to “hypertension,” “diabetes mellitus,” “kidney function

deterioration,” fertility,” and “adverse effects,” in various combinations with “long-term,” “nephro- and ureterolithiasis,” and “lithotripsy.” The detailed search strategy used to query the Medline database is shown in Appendix 1. Additionally, the reference lists of all of the identified publications were searched manually to identify further relevant studies describing long-term adverse effects of ESWL.

Eligibility criteria

Peer-reviewed studies reporting at least one of the four adverse effects of interest (HTN, DM, CKD, FERT) were eligible for inclusion in this review. We excluded studies with fewer than 30 patients and those with a follow-up period of less than one year.

Study selection

Duplicate articles were filtered using the “close match function” within the Endnote citation management software and subsequently two authors (CDF, BK) performed additional manual deduplication. The same two authors screened the titles and abstracts independently to select publications compliant with the eligibility criteria and came to a consensus about inclusion of studies.

Data extraction and synthesis

A data extraction sheet (based on the data extraction template from the Cochrane Consumers and Communication Review Group) was developed and further adapted after pilot testing on five randomly selected eligible studies. Data were collected on study design, length of follow-up, patient characteristics, outcome assessment methods, and outcome definitions for HTN, DM, CKD, and FERT. One investigator (CDF) extracted the data and a second investigator (BK) reviewed the extracted data. Disagreements were discussed and resolved by consensus or by third-party arbitration (JS).

Quality assessment

Study quality was determined using the Scottish Intercollegiate Guidelines Network (SIGN) methodology checklist for cohort studies and randomized controlled trials.⁴ Overall study quality and bias risk were rated according to the SIGN recommendations. Quality ratings were assigned as follows: high, indicating that most criteria were fulfilled and the study conclusions are very unlikely to be altered; moderate, that some criteria were fulfilled and, in cases where the criteria were not fulfilled, the study conclusions are unlikely to be altered; and low, that few or no of the criteria were fulfilled, and conclusions are likely to be altered.

Results

Study selection

The complete study selection process is illustrated in Figure 1. After deduplication, we retrieved 889 citations. Of these, 827 studies were discarded after review of the abstracts because they did not fulfill the eligibility criteria. The full text of 62 publications was reviewed in detail, and a final total of 39 studies matched the inclusion criteria.

Study characteristics

The selected studies were published between 1988 and 2013. Two were randomized controlled trials (RCT) and 37 were cohort studies. The number of patients included ranged from 30 to 1758 in the ESWL study groups. Trial and patient characteristics are summarized in Appendix 2.

Quality of the included studies

The SIGN quality was rated high in 3 studies (8%), moderate in 9 studies (23%), and poor in 27 studies (69%). A detailed summary of the assessment is reported in Appendix 3.

Outcomes of primary interest

Arterial hypertension (HTN)

Of the 30 included studies reporting on the incidence of HTN after ESWL, two were RCTs and 28 were cohort studies. All were published between 1988 and 2012. The number of patients treated with ESWL in each study ranged from 35 to 1758, and median follow-up periods ranged from 12 to 240 months. We found 17 studies describing patients with HTN without any comparison to a control group. Two studies compared the HTN prevalence with a healthy population, whereas the remaining 11 studies matched the ESWL-treated patients with an untreated nephro-/ureterolithiasis population. We identified 10 different blood pressure cut-off levels used to define HTN. In 6 out of 30 studies, the authors concluded that ESWL might be causal for new-onset HTN. No evidence for an increase in the incidence of HTN was reported in the remaining 24 (80%) publications (see Fig. 2). Data were not pooled in a meta-analysis because of heterogeneous definitions of HTN and data acquisition. For individual study results, see Appendix 2, Tables 1 and 2.

Diabetes mellitus (DM)

All six included studies were cohort studies, which were published between 2008 and 2013. The number of ESWL-treated patients ranged from 70 to 772. Four studies incorporated a control group, whereas two describe only a single ESWL cohort. One study retrieved information from an epidemiological register, two studies assessed serum glucose levels, and three studies asked physicians or patients about a potential diagnosis of DM and prescribed anti-diabetic therapy. Follow-up periods ranged from 5 to 20 years. In two studies, the authors concluded that ESWL might be causal for new-onset DM, whereas four studies found no evidence for an increase in the incidence of DM. Due to heterogeneous control groups and use of different methods to obtain the DM status of the patients, study data were not pooled in a meta-analysis. For individual study results, see Appendix 2, Tables 3 and 4.

Chronic kidney disease (CKD)

Of the 14 included studies regarding kidney failure, we retrieved seven retrospective and seven prospective cohort studies, which were published between 1992 and 2012. Median follow-up periods ranged from 15 months to 17 years. One study compared the ESWL cohort with a cohort treated with percutaneous-nephrolithotomy (PNL), whereas another study compared patients with ESWL-treated renal stones to patients with ESWL-treated ureteral stones. One study compared patients with ESWL-treated stones to a cohort of asymptomatic stone carriers. Eleven studies had no control groups. Eleven studies retrieved information about kidney function by looking at laboratory findings, one study by asking the patient about any kidney problems, and two studies did not report precisely how kidney function was assessed. All 14 studies concluded that there is no evidence for an increase in the incidence of CKD after ESWL. Due to the heterogeneous methods used to obtain the patients' kidney function status and varied definitions of kidney function, data were not pooled in a meta-analysis. For individual study results, see Appendix 2, Table 5.

Decreased fertility (FERT)

We were able to identify two retrospective studies focusing on female infertility but none focusing on male infertility. Vieweg⁵ asked 67 women about secondary sterility, contraception, miscarriages, and malformations in their newborns. Of the 67 female patients who answered the questionnaire, only 10 patients were actually trying to conceive after ESWL. Similarly, Erturk⁶ sent out a questionnaire to 39 patients, of which ten mothers reported to have successfully delivered 11 babies in total. For individual study results see Appendix 2, Table 6.

Discussion

From animal studies, in vitro studies, and imaging studies, we have evidence that ESWL can cause histological renal changes, even at low doses, and that it may result in an increase in mean arterial blood pressure by damaging the kidney^{7,8} and other intra-abdominal organs.⁹ Uncertainty prevails regarding long-term adverse effects.

Arterial hypertension (HTN)

While treating renal calculi with ESWL, the kidneys are directly exposed to shockwaves. Shockwaves cause shear stress on the urinary calculi, but as a potential side effect, shockwaves might also damage kidney tissue and could therefore lead to HTN.

In our review, only six out of 30 studies concluded that ESWL might lead to HTN. Of these six studies, three had no controls or comparison of ESWL-treated patients with an average population. A study by Krambeck et al. found an ESWL-related increase in HTN rate in 2006¹⁰ but the authors subsequently published the results of a study focusing on a different cohort with an incidence of HTN not different compared to persons without prior ESWL.¹¹

While comparing PNL and ESWL, Lingeman et al. found a lower annual incidence of HTN among ESWL patients compared to non-ESWL patients, yet also reported a rise in diastolic blood pressure.¹² The evidence presented in the six cohort studies that found an increased new-onset HTN rate after ESWL is weaker compared to that in the other 24 studies, including two RCTs, which found no association (see Appendix 2, Tables 1 and 2).

A systematic review with a meta-analysis regarding the incidence of HTN after ESWL was published recently by Yu.¹³ Despite stating an intention to follow the PRISMA guidelines, no literature research protocol was published, and it seems that the search was performed with very few key words. Perhaps due to our extended research protocol, our study included 19 additional studies compared to the set evaluated by Yu.¹³ In contrast to the approach taken by

Yu,¹³ we waived a meta-analysis because we detected two common pitfalls affecting most of the included studies. First, variation in the definition of HTN cut-off values can change the annualized incidence rate of HTN from 6% to 14%.¹⁴ We note that in the included studies a total of 10 different blood pressure cut-off levels were used to define HTN. Second, the data sources and methods used to obtain blood pressure reading or diagnostic codes were very heterogeneous. In our opinion, the above-described heterogeneity in both the definitions of HTN and the methods to obtain the HTN status make a meta-analysis unadvisable.

Diabetes mellitus (DM)

The pancreas lies in the retroperitoneum and might be exposed to shockwaves with resulting tissue damage during ESWL due to its proximity to the kidneys. Two studies indicated an increase in DM rate after ESWL. The first study, by Kazemi et al., found an 8.1% diabetes prevalence after ESWL in a cohort of 307 patients¹⁵. This prevalence has to be interpreted with caution because no control group was observed. Thus, it remains possible that some metabolic dysfunction resulting in nephro- and ureterolithiasis and DM might result in the higher DM prevalence, rather than the ESWL therapy itself¹⁶. The second study, published by Krambeck et al in 2006,¹⁰ describes a 16.8% incidence of new-onset DM after ESWL, but the authors subsequently published the results of a study focusing on a different cohort with an incidence of DM not different compared to persons without prior ESWL.¹⁷ With only six relevant studies, none of them RCT, it is not possible to make a conclusive statement about whether ESWL might cause DM.

Chronic kidney disease (CKD)

The kidneys are directly exposed to shockwaves when urinary calculi lie within the renal pelvis. Short-term adverse effects after ESWL have been described in detail.¹ However, it is unclear whether the observed acute tissue damage may lead to chronic kidney function deterioration. None of the studies that we reviewed found evidence for an increase in the

incidence of kidney function deterioration after ESWL. Therefore, based on the existing evidence, we conclude that ESWL is not seen to influence kidney function in a negative manner. However, the current literature is limited and therefore cannot give a final statement about possible association of ESWL with kidney failure.

Fertility (FERT)

The uteri/adnexa, their vascular supply, and the vascular supply of the testicles are directly exposed to shockwaves when urinary calculi lie in the distal ureter, therefore raising the question of whether ESWL may compromise male or female fertility. In a systematic review including clinical short term studies, in vitro studies, and animal studies, Philippou et al.¹⁸ could not provide a final statement about male infertility as no studies with long-term follow-up were available at the time. In our current literature research, we identified two studies^{5,6} focusing on female fertility. In both studies, only 10 patients had attempted to become pregnant, which is an insufficient sample size to show any effect of ESWL on fertility. Furthermore, fertility is difficult to define and to assess in a retrospective manner. Therefore, no conclusion about the possible influence of ESWL on fertility can be drawn from the identified studies.

Limitations

The poor methodological quality of the published studies may result in bias. For example, the vast majority of the included studies are retrospective studies, which are prone to bias. Furthermore, most studies do not compare the incidence of LAE between the ESWL patients and an adequate control group. Our search criteria were designed and reviewed by clinicians and librarians and were included in our peer-reviewed protocol. However, it is possible that not all potentially relevant studies were identified due to undetected flaws in our search strategy, and thus this would have to be classified as a potential source of bias.

Conclusions

Currently, no strong evidence supports the hypothesis that ESWL causes long-term adverse effects. Most of the relevant studies from the published literature have to be interpreted with caution because study designs are mostly retrospective, with inadequate control groups, small sample sizes, and short follow-up periods. New studies addressing the above-mentioned weaknesses are needed to reach a final conclusion about long-term adverse effects after ESWL.

References

1. C. Türk TK, A. Petrik, K. Sarica, A. Skolarikos, M. Straub, C. Seitz: Guidelines on Urolithiasis. available at: http://www.uroweb.org/gls/pdf/22%20Urolithiasis_LR.pdf. . Uroweb 2014.
2. Moher D, Liberati A, Tetzlaff J, et al.: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Journal of clinical epidemiology* 2009; 62: 1006-1012.
3. Zorzela L, Golder S, Liu Y, et al.: Quality of reporting in systematic reviews of adverse events: systematic review. *BMJ (Clinical research ed)* 2014; 348: f7668.
4. Harbour R, Lowe G and Twaddle S: Scottish Intercollegiate Guidelines Network: the first 15 years (1993-2008). *The journal of the Royal College of Physicians of Edinburgh* 2011; 41: 163-168.
5. Vieweg J, Weber HM, Miller K, et al.: Female fertility following extracorporeal shock wave lithotripsy of distal ureteral calculi. *Journal of Urology* 1992; 148: 1007-1010.
6. Erturk E, Ptak AM and Monaghan J: Fertility measures in women after extracorporeal shockwave lithotripsy of distal ureteral stones. *Journal of Endourology* 1997; 11: 315-317.
7. Kaude JV, Williams CM, Millner MR, et al.: Renal morphology and function immediately after extracorporeal shock-wave lithotripsy. *AJR American journal of roentgenology* 1985; 145: 305-313.
8. Kaji DM, Xie HW, Hardy BE, et al.: The effects of extracorporeal shock wave lithotripsy on renal growth, function and arterial blood pressure in an animal model. *The Journal of urology* 1991; 146: Pt 2.
9. McAteer JA and Evan AP: The acute and long-term adverse effects of shock wave lithotripsy. *Seminars in nephrology* 2008; 28: 200-213.
10. Krambeck AE, Gettman MT, Rohlinger AL, et al.: Diabetes mellitus and hypertension associated with shock wave lithotripsy of renal and proximal ureteral stones at 19 years of followup. *Journal of Urology* 2006; 175: 1742-1747.
11. Krambeck AE, Rule AD, Li X, et al.: Shock wave lithotripsy is not predictive of hypertension among community stone formers at long-term followup.[Erratum appears in *J Urol.* 2011 Mar;185(3):1161]. *Journal of Urology* 2011; 185: 164-169.

12. Lingeman JE, Woods JR and Toth PD: Blood pressure changes following extracorporeal shock wave lithotripsy and other forms of treatment for nephrolithiasis. *JAMA* 1990; 263: 1789-1794.
13. Yu C, Longfei L, Long W, et al.: A systematic review and meta-analysis of new onset hypertension after extracorporeal shock wave lithotripsy. *International urology and nephrology* 2014; 46: 719-725.
14. Weissfeld JL and Kuller LH: Methodologic evaluation of incidence rates for hypertension: calculated for Pittsburgh's MRFIT usual care men. *Journal of chronic diseases* 1985; 38: 915-925.
15. Kazemi Rashed F, Rash Ahmadi N, Amjadi M, et al.: Does extra corporeal shock wave lithotripsy predispose patients to diabetes mellitus? Prevalence of diabetes mellitus after ESWL in 15 years follow-up. *Life Science Journal* 2013; 10: 152-155.
16. Chung SD, Chen YK and Lin HC: Increased Risk of Diabetes in Patients With Urinary Calculi: A 5-Year Followup Study. *Journal of Urology* 2011; 186: 1888-1893.
17. de Cogain M, Krambeck AE, Rule AD, et al.: Shock wave lithotripsy and diabetes mellitus: a population-based cohort study. *Urology* 2012; 79: 298-302.
18. Philippou P, Ralph DJ and Timoney AG: The impact of shock wave lithotripsy on male fertility: a critical analysis of existing evidence. *Urology* 2012; 79: 492-500.




Figure 1: Selection of extracorporeal shock wave lithotripsy (ESWL) studies. From the initial 889 records that we initially identified, we included 39 studies after the selection process, as illustrated above.

Appendix 2

Table 1 **Studies suggesting no association between ESWL and an increase in the incidence of arterial hypertension**

First Author	Study design	Follow-up time in months (mean or median)	Control group	Identification of patients with arterial hypertension pre= before ESWL post= after ESWL	Definition of arterial hypertension	Results/ Conclusion
Liedel ¹	Retrospective cohort	40	Other group of patients treated with ESWL	Pre: chart review Post: patient reported	RR >160/95 mmHg or prescribed antihypertensive therapy	No evidence for an ESWL-related increased risk of hypertension; no indication for any deterioration of renal function
Montgomery ²	Retrospective cohort	29 (SD 8.4) (range 12-44)	None	Pre: chart review Post: Reported by physicians	Systolic RR > age+100 mmHg, diastolic RR >95mmHg	No change in the mean arterial pressure
Nijman ³	Prospective cohort	24 (range 13-40)	None	Not reported	Not reported	Hypertension did not occur in any patient during follow-up
Puppo ⁴	Retrospective cohort	average not reported (range 12-36)	None	Pre: chart review Post: reported by physician	RR > 130/95 mmHg for women, >140/90 mmHg for men younger 45y and >150/95 mmHg older 45y	No evidence for an increase in the incidence of arterial hypertension
Mays ⁵	Prospective cohort	24	PNL	Post: Reported by patients	Not reported	new medical problem (...) which could be potentially been associated with their renal treatment was found 3% in the PNL, and in 2% in the ESWL

						group
Yokoyama ⁶	Retrospective cohort	18 (SD 17)	None	Pre: chart review Post: Not reported	RR >160/95 mmHg	No evidence for an increase in the incidence of arterial hypertension
Zanetti ⁷	Prospective cohort	29	None	Pre: measured by physician Post: measured by physician	RR >160/95 mmHg	No evidence for an increase in the incidence of arterial hypertension
Carlson ⁸	Retrospective cohort	40 (range 12-56)	PNL	Pre: chart review Post: measured by physician	Not reported	No evidence for an increase in the incidence of arterial hypertension
Claro ⁹	Prospective cohort	22 (range 5-41)	None	Pre: measured by physicians Post: measured by physicians	Diastolic RR >90mmHg	No evidence for an increase in the incidence of arterial hypertension
Simon ¹⁰	Retrospective cohort	24	None	Pre: measured by physicians Post: telephone interview with patient or physician	Not reported	No evidence for an increase in the incidence of arterial hypertension
Sarica ¹¹	Prospective cohort	33 (range 30-39)	None	Pre: measured by physicians Post: measured by physician	Not reported	No evidence for an increase in the incidence of arterial hypertension
Jewett ¹²	RCT	12	asymptomatic stone carriers	Pre: measured by physicians Post: measured by physicians	Diastolic RR >100mmHg	No evidence for an increase in the incidence of arterial hypertension

Appendix 2

Author	Study Question	Comparable groups	Accural rate	Outcome at time of enrolment	Drop outs	Comp. lost to follow-up	Definition of outcomes	Blind assessment	Missing blinding addressed	Reliability	External validity and reliability	Number of assessments	Confounder analysis	Confidence intervals	Bias/confounding overall	Effect is real?	Targeted groups?
Barbosa ¹	Y	N	NA	N	73 %	NA	Y	NA	NA	NA	N	N	N	N	-	N	Y
Brinkmann ²	Y	NA	NA	Y	16 %	N	Y	NA	Y	Y	N	N	N	N	-	Y	Y
Carlson ³	Y	N	NA	Y	45 %	N	Y	NA	NA	NA	N	N	N	N	-	Y	Y
Chew ⁴	Y	N	N	Y	42 .7 %	NA	Y	NA	NA	N	N	N	N	N	-	Y	Y
Claro ⁵	Y	Y	N	Y	16 %	N	Y	NA	NA	Y	Y	Y	N	N	+	Y	Y
Cogain ⁶	Y	Y	NA	Y	NA	NA	Y	NA	NA	NA	NA	N	N	N	+	Y	Y
Eassa ⁷	Y	NA	N	Y	16 %	N	Y	NA	NA	Y	NA	N	N	N	+	Y	Y
El-Assmy ⁸	Y	NA	N	Y	47 %	NA	N	NA	NA	Y	N	N	N	N	-	Y	Y
El-Assmy ⁹	Y	NA	N	Y	31 %	N	N	NA	NA	Y	N	N	N	N	-	Y	Y
El-Nahas ¹⁰	Y	NA	N	Y	30 %	N	Y	NA	NA	N	N	N	N	N	-	Y	Y
Erturk ¹¹	Y	NA	N	N	44 %	N	N	NA	NA	N	N	N	N	N	-	N	Y
Graff ¹²	Y	NA	N	N	43 %	N	N	NA	NA	N	N	N	N	N	-	Y	Y

Janetschek ¹³	Y	NA	N	Y	25 %	N	Y	NA	NA	Y	N	N	N	N	-	Y	Y
Kazemi ¹⁴	Y	NA	Y	Y	78 %	N	Y	NA	NA	Y	Y	N	N	N	-	Y	Y
Knapp ¹⁵	Y	NA	N	Y	0 %	NA	Y	NA	NA	Y	Y	N	N	N	+	Y	Y
Krambeck ¹⁶	Y	Y	Y	Y	41 %	Y	Y	NA	NA	Y	N	N	Y	Y	+	Y	Y
Krambeck ¹⁷	Y	Y	NA	Y	NA	NA	Y	NA	NA	NA	NA	N	N	Y	+	Y	Y
Lingeman ¹⁸	Y	Y	Y	Y	27 %	N	Y	NA	NA	Y	Y	Y	Y	Y	+	Y	Y
Liedl ¹⁹	Y	N	N	N	35.4 %	N	Y	NA	NA	N	Y	N	N	N	-	N	Y
Mays ²⁰	Y	N	NA	N	45 %	N	N	N	N	Y	N	Y	N	N	-	N	Y
Montgomery ²¹	Y	NA	NA	Y	22 %	N	Y	NA	NA	N	N	N	N	Y	-	N	Y
Nijman ²²	Y	NA	N	NA	0 %	N	N	NA	NA	N	N	N	N	N	-	N	Y
Perry ²³	Y	NA	N	N	54 %	N	N	NA	NA	N	N	N	Y	N	-	N	Y
Puppo ²⁴	Y	NA	N	Y	0 %	NA	Y	NA	NA	N	N	N	N	N	-	N	Y
Protogerou ²⁵	Y	NA	N	Y	0 %	N	Y	N	N	Y	Y	Y	N	N	++	Y	Y
Ramakrishnan ²⁶	Y	NA	N	Y	0 %	N	N	NA	NA	N	N	N	N	N	-	Y	Y
Sarica ²⁷	Y	NA	N	Y	0 %	N	Y	NA	NA	Y	N	N	N	N	-	N	Y
Sato ²⁸	Y	Y	Y	Y	70 %	N	Y	NA	NA	N	N	N	Y	Y	+	Y	Y
Simon ²⁹	Y	NA	NA	N	5 %	N	Y	NA	NA	N	N	N	N	N	-	N	Y

Strohmaier ³⁰	Y	Y	N	Y	0 %	N	Y	N	N	Y	Y	Y	N	N	+	Y	Y
Traxer ³¹	Y	NA	N	Y	0 %	N	N	NA	NA	N	N	N	N	N	-	N	Y
Vieweg ³²	Y	NA	NA	N	20 %	N	N	NA	NA	N	N	N	N	N	-	N	Y
Williams ³³	Y	NA	NA	Y	39 %	N	Y	NA	NA	Y	N	N	N	N	-	N	Y
Yokoyama ³⁴	Y	NA	N	Y	0 %	N	Y	NA	NA	Y	N	N	N	N	-	N	Y
Yoo ³⁵	Y	Y	Y	Y	0 %	N	Y	N	N	Y	Y	N	N	N	-	Y	Y
Zanetti ³⁶	Y	NA	N	Y	28 %	N	Y	NA	NA	Y	Y	N	N	N	-	Y	Y
Zanetti ³⁷	Y	NA	N	Y	0 %	NA	Y	NA	NA	N	N	Y	N	N	-	N	Y

Table 1: Study quality determined using the Scottish Intercollegiate Guidelines Network (SIGN) methodology checklist for cohort studies

	Research question adequate	Assignment is randomized	Adequate concealment method	Blinding	Similar treatment and control	Treatment is only difference	Standard, valid and reliable	Drop outs	Intention to treat analysis	Multicenter analysis	Risk of bias or confounding	overall effect is due to the study	Applicable to the patient group
Elves ³⁸	Y	CS	N	NA	Y	Y	Y	12%	N	NA	++	Y	Y
Jewett ³⁹	Y	CS	N	NA	Y	Y	Y	0%	N	NA	++	Y	Y

Table 2: Study quality was determined using the Scottish Intercollegiate Guidelines Network (SIGN) methodology checklist for randomized controlled trials

1. Barbosa PV, Makhlof AA, Thorner D, et al.: Shock wave lithotripsy associated with greater prevalence of hypertension. *Urology* 2011; 78: 22-25.
2. Brinkmann OA, Griehl A, Kuwertz-Broking E, et al.: Extracorporeal shock wave lithotripsy in children. Efficacy, complications and long-term follow-up. *European Urology* 2001; 39: 591-597.
3. Carlson KJ, Dretler SP, Roth RA, et al.: Extracorporeal shock wave lithotripsy and percutaneous nephrostolithotomy for urinary calculi: comparison of immediate and long-term effects. *Journal of Stone Disease* 1993; 5: 8-18.
4. Chew BH, Zavaglia B, Sutton C, et al.: Twenty-year prevalence of diabetes mellitus and hypertension in patients receiving shock-wave lithotripsy for urolithiasis. *BJU international* 2012; 109: 444-449.

5. Claro Jde A, Lima ML, Ferreira U, et al.: Blood pressure changes after extracorporeal shock wave lithotripsy in normotensive patients. *J Urol* 1993; 150: 1765-1767.
6. de Cogain M, Krambeck AE, Rule AD, et al.: Shock wave lithotripsy and diabetes mellitus: a population-based cohort study. *Urology* 2012; 79: 298-302.
7. Eassa WA, Sheir KZ, Gad HM, et al.: Prospective Study of the Long-Term Effects of Shock Wave Lithotripsy on Renal Function and Blood Pressure. *J Urol* 2008; 179: 964-969.
8. El-Assmy A, El-Nahas AR, Madbouly K, et al.: Extracorporeal shock-wave lithotripsy monotherapy of partial staghorn calculi. Prognostic factors and long-term results. *Scandinavian Journal of Urology & Nephrology* 2006; 40: 320-325.
9. el-Assmy A, el-Nahas AR, Hekal IA, et al.: Long-term effects of extracorporeal shock wave lithotripsy on renal function: our experience with 156 patients with solitary kidney. *J Urol* 2008; 179: 2229-2232.
10. El-Nahas AR, Awad BA, El-Assmy AM, et al.: Are there long-term effects of extracorporeal shockwave lithotripsy in paediatric patients? *BJU international* 2013; 111: 666-671.
11. Erturk E, Ptak AM and Monaghan J: Fertility measures in women after extracorporeal shockwave lithotripsy of distal ureteral stones. *Journal of Endourology* 1997; 11: 315-317.
12. Graff J, Diederichs W and Schulze H: Long-term followup in 1,003 extracorporeal shock wave lithotripsy patients. *J Urol* 1988; 140: 479-483.
13. Janetschek G, Frauscher F, Knapp R, et al.: New onset hypertension after extracorporeal shock wave lithotripsy: Age related incidence and prediction by intrarenal resistive index. *J Urol* 1997; 158: 346-351.
14. Kazemi Rashed F, Rash Ahmadi N, Amjadi M, et al.: Does extra corporeal shock wave lithotripsy predispose patients to diabetes mellitus? Prevalence of diabetes mellitus after ESWL in 15 years follow-up. *Life Science Journal* 2013; 10: 152-155.
15. Knapp R, Frauscher F, Helweg G, et al.: Blood pressure changes after extracorporeal shock wave nephrolithotripsy: prediction by intrarenal resistive index. *European Radiology* 1996; 6: 665-669.
16. Krambeck AE, Gettman MT, Rohlinger AL, et al.: Diabetes mellitus and hypertension associated with shock wave lithotripsy of renal and proximal ureteral stones at 19 years of followup. *J Urol* 2006; 175: 1742-1747.
17. Krambeck AE, Rule AD, Li X, et al.: Shock wave lithotripsy is not predictive of hypertension among community stone formers at long-term followup.[Erratum appears in *J Urol*. 2011 Mar;185(3):1161]. *J Urol* 2011; 185: 164-169.
18. Lingeman JE, Woods JR and Toth PD: Blood pressure changes following extracorporeal shock wave lithotripsy and other forms of treatment for nephrolithiasis. *JAMA* 1990; 263: 1789-1794.
19. Liedl B, Jocham D, Lunz C, et al.: Five-Year Follow-up of Urinary Stone Patients Treated with Extracorporeal Shock Wave Lithotripsy, in Lingeman J, and Newman D (Eds): *Shock Wave Lithotripsy*, Springer US, 1988, pp 153-158.
20. Mays N, Petruckevitch A and Burney PG: Results of one and two year follow-up in a clinical comparison of extracorporeal shock wave lithotripsy and percutaneous nephrolithotomy in the treatment of renal calculi. *Scandinavian Journal of Urology & Nephrology* 1992; 26: 43-49.
21. Montgomery BS, Cole RS, Palfrey EL, et al.: Does extracorporeal shockwave lithotripsy cause hypertension? *British Journal of Urology* 1989; 64: 567-571.
22. Nijman RJ, Ackaert K, Scholtmeijer RJ, et al.: Long-term results of extracorporeal shock wave lithotripsy in children. *J Urol* 1989; 142: 609-611; discussion 619.
23. Perry KT, Smith ND, Weiser AC, et al.: The efficacy and safety of synchronous bilateral extracorporeal shock wave lithotripsy. *J Urol* 2000; 164: 644-647.

24. P. P: Hypertension after extracorporeal shock wave lithotripsy: A false alarm. *Journal of Endourology* 1989.
25. Protogerou V, Deliveliotis C, Protogerou A, et al.: Extracorporeal shockwave lithotripsy for kidney stones reduces blood pressure: use of 24-hour ambulatory monitoring for study of blood-pressure changes induced by SWL. *Journal of Endourology* 2004; 18: 17-22.
26. Ramakrishnan PA, Medhat M, Al-Bulushi YH, et al.: Extracorporeal shockwave lithotripsy in infants. *Canadian Journal of Urology* 2007; 14: 3684-3691.
27. Sarica K, Kupei S, Sarica N, et al.: Long-term follow-up of renal morphology and function in children after lithotripsy. *Urologia Internationalis* 1995; 54: 95-98.
28. Sato Y, Tanda H, Kato S, et al.: Shock wave lithotripsy of renal stone is not associated with hypertension and diabetes mellitus. *J Urol* 2007; 177: 431-431.
29. Simon P, Mignard JP, Ang KS, et al.: [Short and long term complications of lithotripsy on renal function]. *Nephrologie* 1993; 14: 305-307.
30. Strohmaier WL, Carl AM, Wilbert DM, et al.: Effects of extracorporeal shock wave lithotripsy on plasma concentrations of endothelin and renin in humans. *J Urol* 1996; 155: 48-51.
31. Traxer O, Lottmann H, Archambaud F, et al.: [Extracorporeal lithotripsy in children. Study of its efficacy and evaluation of renal parenchymal damage by DMSA-Tc 99m scintigraphy: a series of 39 children]. *Archives de Pediatrie* 1999; 6: 251-258.
32. Vieweg J, Weber HM, Miller K, et al.: Female fertility following extracorporeal shock wave lithotripsy of distal ureteral calculi. *J Urol* 1992; 148: 1007-1010.
33. Williams CM, Kaude JV, Newman RC, et al.: Extracorporeal shock-wave lithotripsy: long-term complications. *AJR American journal of roentgenology* 1988; 150: 311-315.
34. Yokoyama M, Shoji F, Yanagizawa R, et al.: Blood pressure changes following extracorporeal shock wave lithotripsy for urolithiasis. *J Urol* 1992; 147: 553-557; discussion 557-558.
35. Yoo DE, Han SH, Oh HJ, et al.: Removal of kidney stones by extracorporeal shock wave lithotripsy is associated with delayed progression of chronic kidney disease. *Yonsei Medical Journal* 2012; 53: 708-714.
36. Zanetti GR, Montanari E, Guarneri A, et al.: Long-term followup after extracorporeal shock wave lithotripsy treatment of kidney stones in solitary kidneys. *J Urol* 1992; 148: 1011-1014.
37. Zanetti G, Montanari E, Trinchieri A, et al.: LONG-TERM FOLLOW-UP OF BLOOD-PRESSURE AFTER EXTRACORPOREAL SHOCK-WAVE LITHOTRIPSY. *Journal of Endourology* 1992; 6: 195-197.
38. Elves AW, Tilling K, Menezes P, et al.: Early observations of the effect of extracorporeal shockwave lithotripsy on blood pressure: a prospective randomized control clinical trial. *BJU international* 2000; 85: 611-615.
39. Jewett MA, Bombardier C, Logan AG, et al.: A randomized controlled trial to assess the incidence of new onset hypertension in patients after shock wave lithotripsy for asymptomatic renal calculi. *J Urol* 1998; 160: 1241-1243.

Traxer ¹³	Prospective cohort	Mean not reported (range 6-96)	None	Not reported	Not reported	No evidence for an increase in the incidence of arterial hypertension
Elves ¹⁴	RCT	26 (range 12-60)	asymptomatic stone carriers	Pre: measured by physicians Post: measured by physician	systolic RR >160mmHg or diastolic RR > 90mmHg	No evidence for an increase in the incidence of arterial hypertension
Strohmaier ¹⁵	Prospective cohort	24	Only ureteral stones	Pre: measured by physicians Post: measured by physicians	Not reported	"No difference between renal and ureteral stones, or between the ESWL treatment and the other groups"
Brinkman ¹⁶	Prospective cohort	45	None	Pre: measured by physicians Post: measured by physicians	Not reported	No evidence for an increase in the incidence of arterial hypertension
Protogeru ¹⁷	Prospective cohort	12	Distal ureteral stones treated with ESWL, or URS	Pre: 24h RR measurement Post: 24h RR measurement	Mean 24h RR value > 125/80 mmHg	"ESWL may be responsible for a drop in blood pressure"
Ramakrishnan ¹⁸	Prospective cohort	90	None	Pre: measured by physicians Post: measured by physicians	Not reported	1 of 39 children developed arterial hypertension
Eassa ¹⁹	Prospective cohort	43 (SD 13) (range 18-57)	None	Pre: measured by physicians/ reported by patients Post: measured by physicians/ reported by patients	RR >140/90 mmHg or prescribed antihypertensive therapy	No evidence for an increase in the incidence of arterial hypertension

El-Assmy ²⁰	Retrospective cohort	45 (SD 42) (range 12-192)	None	Pre: measured by physicians Post: measured by physicians	Not reported	No evidence for an increase in the incidence of arterial hypertension
Sato ²¹	Retrospective cohort	204 (range 132-264)	Ureteral stones treated with ESWL	Patient reported	Diagnosis of arterial hypertension and prescribed antihypertensive therapy	No evidence for an increase in the incidence of arterial hypertension
Chew ²²	Retrospective cohort	240	Canadian community health survey	Post: reported by patients	Diagnosis of arterial hypertension and prescribed antihypertensive therapy	No evidence for an increase in the incidence of arterial hypertension
Krambeck ²³	Retrospective cohort	104 (range 4-300)	Non surgically managed urolithiasis patients	Based on ICD entries of patients in database	Not reported	Failed to identify an association between ESWL and HTN
El Nahas ²⁴	Retrospective cohort	62 (SD 43) (range 25-210)	None	Pre: measured by physicians Post: measured by physicians	Diastolic RR > 95 centile	No evidence for an increase in the incidence of arterial hypertension

Table 2 Studies suggesting an association between ESWL and an increase in the incidence of arterial hypertension

First Author	Study design	Follow-up time in months (mean or median)	Control group	Identification of patients with arterial hypertension pre= before ESWL post= after ESWL	Definition of arterial hypertension	Results/ Conclusion by authors
Williams²⁵	Retrospective cohort	17-21	None	Pre: chart review Post: Reported by physicians	RR > 150/95 mmHg	Statistical increase in diastolic and systolic blood pressure after ESWL "8% of patients developed hypertension"
Lingemann²⁶	Retrospective cohort	96 (SD 9)	PNL, URS	Pre: chart review Post: Reported by physicians	prescribed antihypertensive therapy or diastolic RR >90mmhg	Statistically significant rise in diastolic blood pressure; but no evidence in the increase of the incidence of arterial hypertension
Knapp²⁷	Prospective cohort	mean not reported (range 17-23)	None	Pre: Measured by physicians Post: Measured by physicians	RR >145/95mmhg	Compared with normal prevalence of arterial hypertension in Austria (...) the risk of risk of hypertension is increased in older patients
Janetschek²⁸	Prospective cohort	26 (range 18-31)	None	Post: Measured by physicians	systolic RR >140 mmhg and/or diastolic RR >90 mmhg	There is some evidence that in patients older than 60 years ESWL is associated with new onset of arterial hypertension
Krambeck²⁹	Retrospective cohort	228	Non surgically managed	Post: Reported by	Diagnosis of arterial hypertension and prescribed	New onset hypertension 36.4% in the ESWL compared to 27.4% in the control group

			urolithiasis patients	patients	antihypertensive therapy	ESWL is associated with the development of HTN
Barbosa ³⁰	Retrospective cohort	72	Normal Population from NHANES database	Post: Reported by patients	Diagnosis of arterial hypertension and prescribed antihypertensive therapy	The prevalence of arterial hypertension in the ESWL group increased from 26.7% before to 37.8% after ESWL compared to a matched control group 28% before and 32.5% after ESWL ESWL is associated with the development of HTN

Table 3 Studies suggesting no association between ESWL and an increase in the incidence of diabetes mellitus

First Author	Design	Follow-up time in months (mean or median)	Reference group	Identification of patients with diabetes mellitus pre= before ESWL post= after ESWL	Results/ Conclusion by authors
Sato ²¹	Retrospective cohort	204 (range 132-264)	Ureteral stones treated with ESWL	reported by patients	No evidence for an increase in the incidence of diabetes mellitus
Chew ²²	Retrospective cohort	240	Canadian community health survey	reported by patients	No evidence for an increase in the incidence of diabetes mellitus
Cogain ³¹	Retrospective cohort	104 (range 36-276)	Non-SWL urolithiasis patients	Post: disease codes from an epidemiological	No evidence for an increase in the incidence of diabetes mellitus

				register	
EI-Nahas ²⁴	Retrospective cohort	62.4 (SD 43) (range 25-210)	None	Post: Blood serum glucose levels	No evidence for an increase in the incidence of diabetes mellitus

Table 4 **Studies suggesting an association between ESWL and an increase in the incidence of diabetes mellitus**

First Author	Design	Follow-up time in months (mean or median)	Reference group	Identification of patients with diabetes mellitus pre= before ESWL post= after ESWL	Results/ Conclusion by authors
Krambeck ²⁹	Retrospective cohort	228	Non surgically managed urolithiasis patients	Post: Patient reported	New onset was noted in 16.8 % in eswl and 6.6% in the control group
Kazemi ³²	Retrospective cohort	median not reported (range 180-228)	None	Pre: medical chart review Post: Blood serum glucose levels, diagnosis of diabetes and prescribed anti-diabetic therapy	Evidence that ESWL might be associated with an increase in fasting blood sugar levels

Table 5 Studies suggesting no association between ESWL and an increase in the incidence of chronic kidney disease (CKD)

First Author	Design	Follow-up time in months (mean or median)	Reference group	Identification of patients with KFD pre= before ESWL post= after ESWL	Definition of KFD status	Results/ Conclusion by authors
Graff ³³	Prospective cohort	19 (range 12-26)	None	Not reported	Not reported	During follow-up complete restoration was observed. Serious complications during follow-up were no encountered.
Mays ⁵	Prospective cohort	24	PNL	Post: Reported by patients	Not reported	No evidence for an increase in the incidence of kidney function deterioration after ESWL compared to the PNL group
Zanetti ³⁴	Prospective cohort	15 (range 12-24)	None	Pre: Reported by physicians Post: Reported by physicians	Ultrasound and blood serum creatinine levels	No evidence for an increase in the incidence of kidney function deterioration after ESWL
Simon ¹⁰	Retrospective cohort	24	None	Post: Reported by physicians	Blood serum creatinine	No evidence for an increase in the incidence of kidney function deterioration after ESWL
Sarica ¹¹	Prospective cohort	33 (range 30-39)	None	Post: Ultrasound and laboratory values	Kidney size and parenchymal thickness	“The long-term evaluation of our children proved the safety of this procedure”
Traxer ¹³	Prospective cohort	mean not reported (range 6-96)	None	Not reported	Blood serum creatinine and parenchymal	No parenchymal lesions were observed; values for serum creatinine levels were not

					damage	reported.
Perry ³⁵	Retrospective cohort	21	None	Not reported	Blood serum creatinine	No evidence for an increase in the incidence of kidney function deterioration after ESWL
Brinkmann ¹⁶	Prospective cohort	45	None ²	Pre: measured by physicians Post: measured by physicians	Blood serum creatinine levels, kidney size measured by ultrasound	No evidence for a damage to growing kidneys
EI-Assmy ³⁶	Retrospective cohort	90 (SD 52)	None	Not reported	Not reported	No evidence for an increase in the incidence of kidney function deterioration after ESWL
EI-Assmy ²⁰	Retrospective cohort	46 (SD 42) (range 12-192)	None	Post: measured by physicians	Blood serum creatinine	No evidence for an increase in the incidence of kidney function deterioration after ESWL "Safe in the long run"
Eassa ¹⁹	Prospective cohort	Mean 44 (SD 14) (range 18-57)	None	Post: measured by physicians	Blood serum creatinine	No significant long-term effects on renal function
Sato ²¹	Retrospective cohort	204 (range 132-264)	Ureteral stones treated with ESWL	Pre: reported by patients Post: reported by patients	Reporting hemodialysis	No evidence for an increase in the incidence of kidney function deterioration after ESWL
EI-Nahas ²⁴	Retrospective cohort	62 (SD 43) (range 25-210)	None	measured by physicians	Not reported	no evidence for retardation of renal growth
Yoo ³⁷	Retrospective cohort	20 (SD 13)	Non-ESWL treated urolithiasis patients	Pre: measured by physicians Post: measured by physicians	Blood serum creatinine	ESWL is associated with delayed deterioration of renal function in patients with a preexisting decrease in kidney function

Table 6 **Studies suggesting no association between ESWL and an increase in the incidence of infertility**

First Author	Design	Follow-up time in months (mean or median)	Reference group	Identification of patients with Fertility Status pre= before ESWL post= after ESWL	Results/ Conclusion by authors
Vieweg ³⁸	Retrospective cohort	38 (range 9-68)	None	Patient reported	No evidence for an increase in the incidence of infertility
Erturk ³⁹	Prospective cohort	Not reported	None	Patient reported	No evidence for an increase in the incidence of infertility

- Liedl B, Jocham D, Lunz C, et al.: Five-Year Follow-up of Urinary Stone Patients Treated with Extracorporeal Shock Wave Lithotripsy, in Lingeman J, and Newman D (Eds): *Shock Wave Lithotripsy*, Springer US, 1988, pp 153-158.
- Montgomery BS, Cole RS, Palfrey EL, et al.: Does extracorporeal shockwave lithotripsy cause hypertension? *British Journal of Urology* 1989; 64: 567-571.
- Nijman RJ, Ackaert K, Scholtmeijer RJ, et al.: Long-term results of extracorporeal shock wave lithotripsy in children. *J Urol* 1989; 142: 609-611; discussion 619.
- P. P: Hypertension after extracorporeal shock wave lithotripsy: A false alarm. *Journal of Endourology* 1989.
- Mays N, Petruckevitch A and Burney PG: Results of one and two year follow-up in a clinical comparison of extracorporeal shock wave lithotripsy and percutaneous nephrolithotomy in the treatment of renal calculi. *Scandinavian Journal of Urology & Nephrology* 1992; 26: 43-49.
- Yokoyama M, Shoji F, Yanagizawa R, et al.: Blood pressure changes following extracorporeal shock wave lithotripsy for urolithiasis. *J Urol* 1992; 147: 553-557; discussion 557-558.
- Zanetti G, Montanari E, Trinchieri A, et al.: LONG-TERM FOLLOW-UP OF BLOOD-PRESSURE AFTER EXTRACORPOREAL SHOCK-WAVE LITHOTRIPSY. *Journal of Endourology* 1992; 6: 195-197.
- Carlson KJ, Dretler SP, Roth RA, et al.: Extracorporeal shock wave lithotripsy and percutaneous nephrostolithotomy for urinary calculi: comparison of immediate and long-term effects. *Journal of Stone Disease* 1993; 5: 8-18.
- Claro Jde A, Lima ML, Ferreira U, et al.: Blood pressure changes after extracorporeal shock wave lithotripsy in normotensive patients. *J Urol* 1993; 150: 1765-1767.
- Simon P, Mignard JP, Ang KS, et al.: [Short and long term complications of lithotripsy on renal function]. *Nephrologie* 1993; 14: 305-307.
- Sarica K, Kupei S, Sarica N, et al.: Long-term follow-up of renal morphology and function in children after lithotripsy. *Urologia Internationalis* 1995; 54: 95-98.
- Jewett MA, Bombardier C, Logan AG, et al.: A randomized controlled trial to assess the incidence of new onset hypertension in patients after shock wave lithotripsy for asymptomatic renal calculi. *J Urol* 1998; 160: 1241-1243.

13. Traxer O, Lottmann H, Archambaud F, et al.: [Extracorporeal lithotripsy in children. Study of its efficacy and evaluation of renal parenchymal damage by DMSA-Tc 99m scintigraphy: a series of 39 children]. *Archives de Pediatrie* 1999; 6: 251-258.
14. Elves AW, Tilling K, Menezes P, et al.: Early observations of the effect of extracorporeal shockwave lithotripsy on blood pressure: a prospective randomized control clinical trial. *BJU international* 2000; 85: 611-615.
15. Strohmaier WL, Carl AM, Wilbert DM, et al.: Effects of extracorporeal shock wave lithotripsy on plasma concentrations of endothelin and renin in humans. *J Urol* 1996; 155: 48-51.
16. Brinkmann OA, Griehl A, Kuwertz-Broking E, et al.: Extracorporeal shock wave lithotripsy in children. Efficacy, complications and long-term follow-up. *European Urology* 2001; 39: 591-597.
17. Protogerou V, Deliveliotis C, Protogerou A, et al.: Extracorporeal shockwave lithotripsy for kidney stones reduces blood pressure: use of 24-hour ambulatory monitoring for study of blood-pressure changes induced by SWL. *Journal of Endourology* 2004; 18: 17-22.
18. Ramakrishnan PA, Medhat M, Al-Bulushi YH, et al.: Extracorporeal shockwave lithotripsy in infants. *Canadian Journal of Urology* 2007; 14: 3684-3691.
19. Eassa WA, Sheir KZ, Gad HM, et al.: Prospective Study of the Long-Term Effects of Shock Wave Lithotripsy on Renal Function and Blood Pressure. *J Urol* 2008; 179: 964-969.
20. el-Assmy A, el-Nahas AR, Hekal IA, et al.: Long-term effects of extracorporeal shock wave lithotripsy on renal function: our experience with 156 patients with solitary kidney. *J Urol* 2008; 179: 2229-2232.
21. Sato Y, Tanda H, Kato S, et al.: Shock wave lithotripsy of renal stone is not associated with hypertension and diabetes mellitus. *J Urol* 2007; 177: 431-431.
22. Chew BH, Zavaglia B, Sutton C, et al.: Twenty-year prevalence of diabetes mellitus and hypertension in patients receiving shock-wave lithotripsy for urolithiasis. *BJU international* 2012; 109: 444-449.
23. Krambeck AE, Rule AD, Li X, et al.: Shock wave lithotripsy is not predictive of hypertension among community stone formers at long-term followup.[Erratum appears in *J Urol*. 2011 Mar;185(3):1161]. *J Urol* 2011; 185: 164-169.
24. El-Nahas AR, Awad BA, El-Assmy AM, et al.: Are there long-term effects of extracorporeal shockwave lithotripsy in paediatric patients? *BJU international* 2013; 111: 666-671.
25. Williams CM, Kaude JV, Newman RC, et al.: Extracorporeal shock-wave lithotripsy: long-term complications. *AJR American journal of roentgenology* 1988; 150: 311-315.
26. Lingeman JE, Woods JR and Toth PD: Blood pressure changes following extracorporeal shock wave lithotripsy and other forms of treatment for nephrolithiasis. *JAMA* 1990; 263: 1789-1794.
27. Knapp R, Frauscher F, Helweg G, et al.: Blood pressure changes after extracorporeal shock wave nephrolithotripsy: prediction by intrarenal resistive index. *European Radiology* 1996; 6: 665-669.
28. Janetschek G, Frauscher F, Knapp R, et al.: New onset hypertension after extracorporeal shock wave lithotripsy: Age related incidence and prediction by intrarenal resistive index. *J Urol* 1997; 158: 346-351.
29. Krambeck AE, Gettman MT, Rohlinger AL, et al.: Diabetes mellitus and hypertension associated with shock wave lithotripsy of renal and proximal ureteral stones at 19 years of followup. *J Urol* 2006; 175: 1742-1747.
30. Barbosa PV, Makhlof AA, Thorner D, et al.: Shock wave lithotripsy associated with greater prevalence of hypertension. *Urology* 2011; 78: 22-25.
31. de Cogain M, Krambeck AE, Rule AD, et al.: Shock wave lithotripsy and diabetes mellitus: a population-based cohort study. *Urology* 2012; 79: 298-302.

32. Kazemi Rashed F, Rash Ahmadi N, Amjadi M, et al.: Does extra corporeal shock wave lithotripsy predispose patients to diabetes mellitus? Prevalence of diabetes mellitus after ESWL in 15 years follow-up. *Life Science Journal* 2013; 10: 152-155.
33. Graff J, Diederichs W and Schulze H: Long-term followup in 1,003 extracorporeal shock wave lithotripsy patients. *J Urol* 1988; 140: 479-483.
34. Zanetti GR, Montanari E, Guarneri A, et al.: Long-term followup after extracorporeal shock wave lithotripsy treatment of kidney stones in solitary kidneys. *J Urol* 1992; 148: 1011-1014.
35. Perry KT, Smith ND, Weiser AC, et al.: The efficacy and safety of synchronous bilateral extracorporeal shock wave lithotripsy. *J Urol* 2000; 164: 644-647.
36. El-Assmy A, El-Nahas AR, Madbouly K, et al.: Extracorporeal shock-wave lithotripsy monotherapy of partial staghorn calculi. Prognostic factors and long-term results. *Scandinavian Journal of Urology & Nephrology* 2006; 40: 320-325.
37. Yoo DE, Han SH, Oh HJ, et al.: Removal of kidney stones by extracorporeal shock wave lithotripsy is associated with delayed progression of chronic kidney disease. *Yonsei Medical Journal* 2012; 53: 708-714.
38. Vieweg J, Weber HM, Miller K, et al.: Female fertility following extracorporeal shock wave lithotripsy of distal ureteral calculi. *J Urol* 1992; 148: 1007-1010.
39. Erturk E, Ptak AM and Monaghan J: Fertility measures in women after extracorporeal shockwave lithotripsy of distal ureteral stones. *Journal of Endourology* 1997; 11: 315-317.